The combination of mezigdomide and dexamethasone exhibited activity among patients with heavily pretreated multiple myeloma, according to study results published in The New England Journal of Medicine.
“This study represents the culmination of discoveries made over the past decade related to the mechanism of action of immunomodulatory agents in multiple myeloma,” Paul G. Richardson, MD, director of clinical research and clinical program leader at Jerome Lipper Multiple Myeloma Center at Dana-Farber Cancer Institute and professor of medicine at Harvard Medical School, and colleagues
